Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/nature21398 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Corrigendum to: Re-induction With Intravenous Ustekinumab in Patients With Crohn's Disease and a Loss of Response to This Therapy.
Inflamm Bowel Dis
January 2022
Hospital Universitario de Fuenlabrada, Instituto de Investigación Sanitaria del Hospital La Paz (IdiPaz), Madrid, Spain.
Corrigendum to "Role of UHRF1 in malignancy and its function as a therapeutic target for molecular docking towards the SRA domain" [Int. J. Biochem. Cell Biol. 114 (September 2019) 105558].
Int J Biochem Cell Biol
September 2019
Department of Pharmacy Practice, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, Karnataka, 576104, India. Electronic address:
Cancer pathogenesis has been attributed to the minor and major disruptions in the cell cycle, with a key role being played by several of the recently discovered epigenetic factors. Lately, UHRF1 (Ubiquitin-like with containing PHD and RING Finger domains 1), an epigenetic regulator has been shown to be evidently over expressed in numerous malignancies through an in-depth review of literature. Molecular docking studies have found that existing drugs such as propranolol, naphthazarin and thymoquinone have favourable interactions with specific domains of UHRF1.
View Article and Find Full Text PDFCorrigendum to "Argentinean recommendations on the identification of treatment failure in relapsing remitting multiple sclerosis patients" [J. Neurol. Sci. 385C (2018) 217-224].
J Neurol Sci
April 2018
Department of Neurology, Institute for Neurological Research Dr Raul Carrea, FLENI,Argentina.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!